RDY and DRREDDY Related Headlines
Go Back- Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
- Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
- FDA accepts Dr. Reddy's biosimilar abatacept application for review
- Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
- Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
- Aurigene reports 63.6% response rate in early cancer drug trial
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
- Dr. Reddy’s Q1FY26 Financial Results
RDY and DRREDDY Related Press Releases
Go Back- Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
- Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
- Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
- Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
- Dr. Reddy’s Q1FY26 Financial Results
